ESR1 and triple-negative breast carcinoma: As a pilot study, several encouraging immune responses were observed by stimulated ELIspot assays in both estrogen receptor positive and estrogen receptor negative participants (notably this trial was designed prior to an understanding of triple negative breast cancer as a comparatively more immunogenic subtype).